Transjugular intrahepatic portosystemic shunt (TIPS) can help resolve portal hypertension (pHTN) in patients with myeloproliferative neoplasms (MPNs), according to a retrospective analysis involving 29 individuals. However, TIPS thrombosis occurs frequently.
Participants with MPNs underwent TIPS at 3 academic medical centers between 1997 and 2016. Investigators looked at safety and long-term outcomes. Among the results:
- Most patients experienced complete clinical resolution of pHTN and its clinical sequelae following TIPS.
- Overall survival at 1 year was 96%; at 2, 3, and 4 years these rates were 92%, 85%, and 71%, respectively.
- However, even with therapeutic anticoagulation, in-stent thrombosis occurred in 31% of patients after TIPS.
The authors advised indefinite anticoagulation post-TIPS.
Reilly C, Babushok D, Martin K, et al. Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt (TIPS) for management of MPN-associated portal hypertension. [Published online ahead of print May 24, 2017]. Am J Hematol. doi:10.1002/ajh.24798.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al